JPH07502651A - 老化細胞由来dna合成阻害因子 - Google Patents
老化細胞由来dna合成阻害因子Info
- Publication number
- JPH07502651A JPH07502651A JP5511170A JP51117093A JPH07502651A JP H07502651 A JPH07502651 A JP H07502651A JP 5511170 A JP5511170 A JP 5511170A JP 51117093 A JP51117093 A JP 51117093A JP H07502651 A JPH07502651 A JP H07502651A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- vol
- nucleic acid
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (15)
- 1.受容細胞におけるDNA合成を阻害する能力のあるタンパク質をコードする 核酸分子。
- 2.該分子がDNAであり、かつDNAプラスミドに組み込まれている、請求の 範囲1項記載の核酸分子。
- 3.該分子かSD1−1である、請求の範囲2項記載の核酸分子。
- 4.該分子が図5<配列番号1>で示される配列を有する、請求の範囲2項記載 の核酸分子。
- 5.該プラスミドがpcDSRαΔである、請求の範囲3項記載の核酸分子。
- 6.該分子がRNAである、請求の範囲1項記載の核酸分子。
- 7.請求の範囲6項記載のRNA分子に相補的な配列と、該分子を生理学的条件 下でもう一方とハイブリダイズさせるのに十分な長さを有する核酸分子。
- 8.RNA分子である、請求の範囲7項記載の核酸分子。
- 9.DNA分子である、請求の範囲7項記載の核酸分子。
- 10.受容細胞におけるDNA合成を阻害する能力を有するタンパク質をコード する核酸分子の有効量をヒト細胞に与えることを含んで成る、ヒト細胞における DNA合成を阻害する方法。
- 11.該細胞が腫瘍細胞である、請求の範囲10項記載の方法。
- 12.該細胞がイン・ビトロ培養における細胞である、請求の範囲10項記載の 方法。
- 13.受容細胞におけるDNA合成を阻害する能力を有するタンパク質をコード するRNA分子に相補的な配列を有し、該核酸分子および該RNA分子を生理学 的条件下でもう一方とハイブリダイズさせるのに十分な長さを有する核酸分子の 有効量をヒト細胞に与えることを含んで成る、静止または老化ヒト細胞における DNA合成の阻害を抑制解除させる方法。
- 14.該細胞が皮膚細胞である、請求の範囲13項記載の方法。
- 15.該細胞か損傷または火傷組織に存在する、請求の範囲13項記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80852391A | 1991-12-16 | 1991-12-16 | |
US808,523 | 1991-12-16 | ||
US970,462 | 1992-11-02 | ||
US07/970,462 US5302706A (en) | 1991-12-16 | 1992-11-02 | Senescent cell derived inhibitors of DNA synthesis |
PCT/US1992/010904 WO1993012251A1 (en) | 1991-12-16 | 1992-12-15 | Senescent cell derived inhibitors of dna synthesis |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07502651A true JPH07502651A (ja) | 1995-03-23 |
JP3865766B2 JP3865766B2 (ja) | 2007-01-10 |
Family
ID=27123138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51117093A Expired - Fee Related JP3865766B2 (ja) | 1991-12-16 | 1992-12-15 | 老化細胞由来dna合成阻害因子 |
Country Status (12)
Country | Link |
---|---|
US (3) | US5302706A (ja) |
EP (1) | EP0640143B1 (ja) |
JP (1) | JP3865766B2 (ja) |
AT (1) | ATE199740T1 (ja) |
AU (1) | AU673992B2 (ja) |
CA (1) | CA2125974C (ja) |
DE (1) | DE69231739T2 (ja) |
DK (1) | DK0640143T3 (ja) |
ES (1) | ES2157215T3 (ja) |
GR (1) | GR3035905T3 (ja) |
PT (1) | PT640143E (ja) |
WO (1) | WO1993012251A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998029544A1 (fr) * | 1996-12-26 | 1998-07-09 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau peptide, nouvel adn et nouvel anticorps |
US7087582B1 (en) | 1995-09-26 | 2006-08-08 | Regents Of The University Of Michigan | Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21 |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372249B1 (en) * | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
US5302706A (en) * | 1991-12-16 | 1994-04-12 | Baylor College Of Medicine | Senescent cell derived inhibitors of DNA synthesis |
US5744300A (en) * | 1993-03-24 | 1998-04-28 | Geron Corporation | Methods and reagents for the identification and regulation of senescence-related genes |
CA2170641C (en) * | 1993-08-30 | 2011-11-15 | James R. Smith | Senescent cell-derived inhibitors of dna synthesis |
DE69435309D1 (de) * | 1993-08-30 | 2010-09-30 | Baylor College Medicine | Inhibitoren der dna synthese aus alternden zellen |
US6051376A (en) * | 1994-09-30 | 2000-04-18 | The Trustees Of Columbia University In The City Of New York | Uses of mda-6 |
WO1995011986A1 (en) * | 1993-10-27 | 1995-05-04 | The Trustees Of Columbia University In The City Of New York | METHOD FOR GENERATING A SUBTRACTED cDNA LIBRARY AND USES OF THE GENERATED LIBRARY |
WO1995013375A1 (en) * | 1993-11-10 | 1995-05-18 | The Johns Hopkins University | Tumor suppressor waf1 |
US5491069A (en) * | 1994-02-18 | 1996-02-13 | The Regents Of The University Of California | Biomarkers of cell senescence |
US5856121A (en) * | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
AU2589095A (en) * | 1994-05-16 | 1995-12-05 | Washington University | Cell membrane fusion composition and method |
EP0783317B1 (en) * | 1994-05-24 | 2004-11-24 | Baylor College Of Medicine | Mimetics of senescent cell derived inhibitors of dna synthesis |
US5631156A (en) * | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
WO1996012506A1 (en) * | 1994-10-24 | 1996-05-02 | Baylor College Of Medecine | Senescent cell-derived inhibitors of dna synthesis |
GB9422175D0 (en) | 1994-11-03 | 1994-12-21 | Univ Dundee | Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof |
WO1996015245A1 (en) * | 1994-11-11 | 1996-05-23 | Arch Development Corporation | A process of inhibiting non-neoplastic pathological cell proliferation |
US5700927A (en) * | 1994-12-23 | 1997-12-23 | The Children's Medical Center Corporation | Tbc1 gene and uses thereof |
PT817858E (pt) | 1995-03-09 | 2003-09-30 | Gsf Forschungszentrum Umwelt U | Preparacoes fotoprotectoras que compreendem derivados de triazina |
US6149945A (en) * | 1995-03-20 | 2000-11-21 | Alberta Cancer Board | Human fibroblast diffusable factors |
US6025480A (en) * | 1995-04-03 | 2000-02-15 | Sloan-Kettering Institute For Cancer Research | Isolated nucleic acid molecules encoding P57KIP2 |
US6322548B1 (en) | 1995-05-10 | 2001-11-27 | Eclipse Surgical Technologies | Delivery catheter system for heart chamber |
GB9509557D0 (en) | 1995-05-11 | 1995-07-05 | Univ Dundee | PCNA binding substance |
US6224584B1 (en) | 1997-01-14 | 2001-05-01 | Eclipse Surgical Technologies, Inc. | Therapeutic and diagnostic agent delivery |
US5840059A (en) * | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
CA2227370A1 (en) * | 1995-07-20 | 1997-02-06 | Worcester Foundation For Biomedical Research, Inc. | Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene |
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US5705350A (en) * | 1995-08-29 | 1998-01-06 | Duke University | Transcription factor complexes in senescent cells |
US7074398B1 (en) | 1995-10-13 | 2006-07-11 | Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh | Retroviral vectors carrying senescent cell derived inhibitors 1 (SDI-1)or antisense SDI-1 nucleotide sequences |
WO1997013867A1 (en) * | 1995-10-13 | 1997-04-17 | Bavarian Nordic Research Institute | Retroviral vectors carrying senescent cell derived inhibitors 1 (sdi-1) or antisense sdi-1 nucleotide sequences |
GB9600518D0 (en) * | 1996-01-11 | 1996-03-13 | Ludwig Inst Cancer Res | Regulator of cell proliferation |
US5958769A (en) * | 1996-01-18 | 1999-09-28 | Fred Hutchinson Cancer Research Center | Compositions and methods for mediating cell cycle progression |
AU705640B2 (en) * | 1996-01-18 | 1999-05-27 | Fred Hutchinson Cancer Research Center | Compositions and methods for mediating cell cycle progression |
US20030027777A1 (en) * | 1996-04-10 | 2003-02-06 | Andrew Koff | Methods for enhancing animal growth and cell proliferation by elimination of the cyclin-dependent kinase inhibitor function of p27Kip1 |
ATE333465T1 (de) * | 1996-05-08 | 2006-08-15 | Cyclacel Ltd | Methoden und mittel zur hemmung der cdk4- aktivität |
CA2272341A1 (en) * | 1996-11-21 | 1998-05-28 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
US6218109B1 (en) | 1997-09-05 | 2001-04-17 | Baylor College Of Medicine | Mammalian checkpoint genes and proteins |
US6518017B1 (en) * | 1997-10-02 | 2003-02-11 | Oasis Biosciences Incorporated | Combinatorial antisense library |
US20030165888A1 (en) * | 2001-07-18 | 2003-09-04 | Brown Bob D. | Oligonucleotide probes and primers comprising universal bases for diagnostic purposes |
HUP0004512A3 (en) | 1997-10-27 | 2003-01-28 | Agouron Pharmaceuticals Inc La | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
US6489305B1 (en) * | 1998-05-08 | 2002-12-03 | Canji, Inc. | Methods and compositions for the treatment of ocular diseases |
US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
WO2000061810A1 (en) * | 1999-04-08 | 2000-10-19 | Oasis Biosciences, Inc. | Antisense oligonucleotides comprising universal and/or degenerate bases |
US6706491B1 (en) * | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
US20020156247A1 (en) * | 2000-01-12 | 2002-10-24 | Elledge Stephen J. | Mammalian checkpoint genes and proteins |
NZ546983A (en) * | 2003-11-24 | 2009-05-31 | Canji Inc | Reduction of dermal scarring |
ES2403558T3 (es) | 2004-08-27 | 2013-05-20 | Cyclacel Limited | Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI890312A (fi) * | 1988-01-25 | 1989-07-26 | Oncogen | Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein. |
JPH05501500A (ja) * | 1989-10-18 | 1993-03-25 | クリエイティブ・バイオマリキュールズ・インコーポレーテッド | TGF―βの生合成構築物 |
EP0525054A4 (en) * | 1990-04-04 | 1993-05-12 | American National Red Cross | Modified heparin binding growth factors |
IE911115A1 (en) * | 1990-04-10 | 1991-10-23 | Canji Inc | Gene therapy for cell proliferative diseases |
US5302706A (en) * | 1991-12-16 | 1994-04-12 | Baylor College Of Medicine | Senescent cell derived inhibitors of DNA synthesis |
-
1992
- 1992-11-02 US US07/970,462 patent/US5302706A/en not_active Expired - Lifetime
- 1992-12-15 AT AT93901236T patent/ATE199740T1/de not_active IP Right Cessation
- 1992-12-15 DK DK93901236T patent/DK0640143T3/da active
- 1992-12-15 JP JP51117093A patent/JP3865766B2/ja not_active Expired - Fee Related
- 1992-12-15 WO PCT/US1992/010904 patent/WO1993012251A1/en active IP Right Grant
- 1992-12-15 CA CA002125974A patent/CA2125974C/en not_active Expired - Fee Related
- 1992-12-15 DE DE69231739T patent/DE69231739T2/de not_active Expired - Lifetime
- 1992-12-15 EP EP93901236A patent/EP0640143B1/en not_active Expired - Lifetime
- 1992-12-15 PT PT93901236T patent/PT640143E/pt unknown
- 1992-12-15 AU AU33243/93A patent/AU673992B2/en not_active Ceased
- 1992-12-15 ES ES93901236T patent/ES2157215T3/es not_active Expired - Lifetime
-
1994
- 1994-01-03 US US08/160,814 patent/US5424400A/en not_active Expired - Lifetime
-
1995
- 1995-09-06 US US08/524,218 patent/US5840845A/en not_active Expired - Lifetime
-
2001
- 2001-05-22 GR GR20010400759T patent/GR3035905T3/el not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087582B1 (en) | 1995-09-26 | 2006-08-08 | Regents Of The University Of Michigan | Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21 |
WO1998029544A1 (fr) * | 1996-12-26 | 1998-07-09 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau peptide, nouvel adn et nouvel anticorps |
US6579850B1 (en) | 1996-12-26 | 2003-06-17 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide, novel DNA and novel antibody |
US7667005B2 (en) | 1996-12-26 | 2010-02-23 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Polypeptide, novel DNA and novel antibody |
Also Published As
Publication number | Publication date |
---|---|
US5424400A (en) | 1995-06-13 |
CA2125974A1 (en) | 1993-06-24 |
US5302706A (en) | 1994-04-12 |
DK0640143T3 (da) | 2001-07-16 |
EP0640143A1 (en) | 1995-03-01 |
AU673992B2 (en) | 1996-12-05 |
EP0640143A4 (en) | 1996-10-23 |
CA2125974C (en) | 1999-06-29 |
DE69231739T2 (de) | 2001-09-13 |
EP0640143B1 (en) | 2001-03-14 |
US5840845A (en) | 1998-11-24 |
GR3035905T3 (en) | 2001-08-31 |
AU3324393A (en) | 1993-07-19 |
ATE199740T1 (de) | 2001-03-15 |
WO1993012251A1 (en) | 1993-06-24 |
PT640143E (pt) | 2001-09-27 |
DE69231739D1 (de) | 2001-04-19 |
JP3865766B2 (ja) | 2007-01-10 |
ES2157215T3 (es) | 2001-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07502651A (ja) | 老化細胞由来dna合成阻害因子 | |
Rudnicki et al. | Actin and myosin expression during development of cardiac muscle from cultured embryonal carcinoma cells | |
KR100355111B1 (ko) | 발췌제거cDNA라이브러리제조법및제조된라이브러리의용도 | |
AU698841B2 (en) | Methods and reagents for the identification and regulation of senescence-related genes | |
Nakamura et al. | LRIG1 inhibits STAT3-dependent inflammation to maintain corneal homeostasis | |
US20100311161A1 (en) | Method for tissue regeneration | |
JP2007312778A (ja) | HMG蛋白質(highmobilitygroupprotein)遺伝子の核酸配列およびそれらの使用 | |
Braghetta et al. | Overlapping, complementary and site-specific expression pattern of genes of the EMILIN/Multimerin family | |
Pochampally et al. | Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects | |
Grover et al. | The gene organization, chromosome location, and expression of a 55-kDa matrix protein (PRELP) of human articular cartilage | |
JP2002514043A (ja) | 内胚葉、心臓、および神経の誘導因子 | |
Koji et al. | Localization in situ of c-myc mRNA and c-myc protein in adult mouse testis | |
JP2003512304A (ja) | 医薬組成物および分泌フリズル化関連タンパクを用いる方法 | |
Müller et al. | Evidence that expression of c‐fos protein in amnion cells is regulated by external signals. | |
JPH09502094A (ja) | 老化細胞由来dna合成阻害因子 | |
US20040072259A1 (en) | Methods and products for manipulating hematopoietic stem cells | |
Keyes et al. | Regulation of apoptosis in the endocardial cushions of the developing chick heart | |
KR100692226B1 (ko) | 신규 폴리펩티드, 그 폴리펩티드를 암호화하는 cDNA 및 그 용도 | |
WO2019144971A1 (zh) | Icam-1标记及其应用 | |
US20120201792A1 (en) | Methods and products for manipulating hematopoietic stem cells | |
KR20080044205A (ko) | 저산소 스트레스 응답에 관여하는 Int6 단백질, 및 그 용도 | |
Lemanski et al. | Cellular, molecular, and developmental studies on heart development in normal and cardiac mutant axolotls, Ambystoma mexicanum | |
CN114957439B (zh) | 绵羊pdgfd、编码pdgfd核酸及其重组慢病毒、宿主细胞与应用 | |
Li et al. | A homologue of the calcium‐binding disulfide isomerase CaBP1 is expressed in the developing CNS of Drosophila melanogaster | |
US20040241683A1 (en) | Hsst and angiogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060802 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061004 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091013 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101013 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111013 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111013 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111013 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111013 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111013 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121013 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |